Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
SURGERY	O
Allergies:	O
Paxil	O
/	O
Beta-Blockers	O
(Beta-Adrenergic	O
Blocking	O
Agts)	O
/	O
Amoxicillin	O
Attending:	O
___.	O
Chief	O
Complaint:	O
Esophageal	O
carcinoma	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
Minimally	O
invasive	O
esophagogastrectomy	O
with	O
cervical	O
anastomosis	O
and	O
jejunostomy	O
tube	O
placement.	O
History	O
of	O
Present	O
Illness:	O
___	O
gentleman	O
who	O
has	O
been	O
diagnosed	O
with	O
esophageal	O
cancer,	O
who	O
received	O
neoadjuvant	O
chemoradiation.	O
He	O
had	O
a	O
good	O
response	O
to	O
treatment	O
with	O
increasing	O
appetite	O
and	O
decreasing	O
dysphagia.	O
He	O
is	O
not	O
having	O
any	O
nausea	O
or	O
vomiting,	O
but	O
complains	O
of	O
dry	O
cough.	O
He	O
has	O
lost	B-Weight_loss
approximately	O
14	O
pounds.	B-Weight_loss
He	O
underwent	O
a	O
minimally	O
invasive	O
esophagogastrectomy	O
with	O
cervical	O
anastomosis	O
and	O
jejunostomy	O
tube	O
placement.	O
He	O
was	O
admitted	O
to	O
the	O
General	O
Surgical	O
Service	O
for	O
further	O
evaluation	O
and	O
treatment.	O
Review	O
of	O
systems	O
is	O
notable	O
for	O
a	O
history	O
of	O
prostatitis	O
and	O
arthritis.	O
Otherwise,	O
negative	O
in	O
detail.	O
Past	O
Medical	O
History:	O
Past	O
Medical	O
History:	O
1.	O
esophageal	O
cancer	O
2.	O
renal	O
insufficiency	O
3.	O
atrial	O
fibrillation	O
4.	O
stroke	O
5.	O
seizure	B-Seizures
.	O
Past	O
Surgical	O
History:	O
1.	O
inguinal	O
hernia	O
repair	O
2.	O
left	O
hip	O
replacement	O
Social	O
History:	O
___	O
Family	O
History:	O
Notable	O
for	O
a	O
sister	O
with	O
uterine	O
cancer	O
and	O
a	O
mother	O
with	O
diabetes.	O
Physical	O
Exam:	O
Vitals:	O
T:	O
98.6	O
HR:	O
71	O
BP:	O
123/52	O
RR:	O
20	O
SaO2:	O
95%RA	O
NAD	O
RRR	O
Lungs:	O
Expiratory	O
ronchi	O
diffusely,	O
no	O
use	O
of	O
excessory	O
muscles	O
Abdomen:	O
Soft,	O
non-tender,	O
non-distended.	O
J-tube	O
in	O
place	O
without	O
surrounding	O
erythema	O
or	O
drainage.	O
Wound:	O
Neck	O
wound	O
with	O
some	O
purulent	O
drainage	O
overnight,	O
none	O
in	O
AM.	O
No	O
induration	O
around	O
the	O
area.	O
Extremities:	O
Mild	O
pitting	O
edema	O
Pertinent	O
Results:	O
Pertinent	O
Labs:	O
INR:	O
___	O
08:00AM	O
BLOOD	O
___	O
___	O
09:35AM	O
BLOOD	O
___	O
___	O
02:41AM	O
BLOOD	O
___	O
___	O
08:15AM	O
BLOOD	O
___	O
___	O
07:45AM	O
BLOOD	O
___	O
.	O
Others:	O
___	O
09:35AM	O
BLOOD	O
WBC-8.8	O
RBC-2.68*	O
Hgb-8.5*	O
Hct-27.1*	O
MCV-101*	O
MCH-31.6	O
MCHC-31.3	O
RDW-14.6	O
Plt	O
___	O
___	O
08:00AM	O
BLOOD	O
Glucose-149*	O
UreaN-36*	O
Creat-1.3*	O
Na-143	O
K-3.8	O
Cl-101	O
HCO3-29	O
AnGap-17	O
___	O
11:11AM	O
BLOOD	O
cTropnT-0.03*	O
___	O
08:00AM	O
BLOOD	O
Calcium-8.2*	O
Phos-2.7	O
Mg-1.8	O
___	O
06:21AM	O
BLOOD	O
Type-ART	O
pO2-71*	O
pCO2-36	O
pH-7.54*	O
calTCO2-32*	O
Base	O
XS-7	O
___	O
01:37AM	O
BLOOD	O
freeCa-1.16	O
.	O
Microbiology:	O
___	O
SCREEN	O
(Final	O
___:	O
No	O
MRSA	O
isolated.	O
.	O
Pathology:	O
#	O
Esophageal	O
Tissue/Lymph	O
Node:	O
SURGICAL	O
PATHOLOGY	O
REPORT	O
-	O
Final	O
PATHOLOGIC	O
DIAGNOSIS:	O
1.	O
Level	O
nine	O
lymph	O
node,	O
excisional	O
biopsy	O
(1A):	O
One	O
lymph	O
node	O
with	O
no	O
carcinoma	O
seen	O
(___).	O
2.	O
Level	O
3	O
lymph	O
node,	O
excisional	O
biopsy	O
(2A):	O
One	O
lymph	O
node	O
with	O
no	O
carcinoma	O
seen	O
(___).	O
3.	O
Level	O
eight	O
lymph	O
node,	O
excisional	O
biopsy	O
(3A):	O
One	O
lymph	O
nodes	O
with	O
no	O
carcinoma	O
seen	O
(___).	O
4.	O
Esophagus,	O
partial	O
esophagogastrectomy	O
(4A-4AP):	O
A.	O
Minute	O
foci	O
of	O
residual,	O
poorly	O
differentiated	O
adenocarcinoma	O
of	O
the	O
distal	O
esophagus/gastroesophageal	O
junction;	O
see	O
synoptic	O
report	O
and	O
note.	O
B.	O
Eleven	O
lymph	O
nodes	O
with	O
focally	O
prominent	O
hemorrhage,	O
sinus	O
histiocytosis	O
and	O
reactive	O
changes;	O
no	O
carcinoma	O
seen	O
(___).	O
C.	O
Gastric	O
segment	O
with	O
focal	O
chronic,	O
predominantly	O
inactive	O
gastritis;	O
H.	O
pylori	O
immunostains	O
are	O
negative,	O
with	O
satisfactory	O
positive	O
control	O
(performed	O
on	O
blocks	O
4P	O
and	O
4	O
W).	O
Note:	O
The	O
patient	O
is	O
reportedly	O
clinically	O
status-post	O
neadjuvant	O
therapy	O
for	O
a	O
biopsy	O
proven,	O
poorly	O
differentiated	O
adenocarcinoma.	O
No	O
gross	O
lesion	O
is	O
identified.	O
Demonstrated	O
within	O
the	O
distal	O
esophagus/gastroesophageal	O
junction	O
is	O
focal	O
ulceration	O
with	O
marked	O
underlying	O
inflammation	O
and	O
stromal	O
changes,	O
consistent	O
with	O
neoadjuvant	O
therapy	O
effect.	O
Within	O
some	O
of	O
these	O
areas,	O
rare	O
single	O
atypical	O
cells/small	O
clusters	O
are	O
seen	O
within	O
the	O
mucosa	O
and	O
superficial	O
submucosa,	O
and	O
very	O
focally	O
within	O
the	O
deep	O
submucosa	O
and	O
superficial	O
muscularis	O
propria,	O
consistent	O
with	O
focal	O
residual	O
adenocarcinoma	O
with	O
marked	O
treatment	O
effect	O
(confirmed	O
by	O
immunostain	O
for	O
cytokeratin	O
cocktail,	O
performed	O
on	O
blocks	O
4E,	O
4O,	O
4AB,	O
4AG.	O
Seen	O
best	O
on	O
4AG).	O
One	O
large	O
para-esophageal	O
lymph	O
node	O
demonstrating	O
marked	O
hemorrhage	O
and	O
sinus	O
histiocytosis	O
is	O
identified,	O
likely	O
representing	O
the	O
reportedly	O
previously	O
aspirated	O
lymph	O
node	O
with	O
treatment	O
effect.	O
No	O
overt	O
residual	O
nodal	O
metastasis	O
is	O
identified.	O
Esophagus:	O
Resection	O
Synopsis	O
Staging	O
according	O
to	O
___	O
Joint	O
Committee	O
on	O
Cancer	O
Staging	O
Manual	O
--	O
___	O
Edition,	O
___	O
Macroscopic	O
Specimen	O
Type:	O
Esophagogastrectomy	O
Specimen	O
Size:	O
Greatest	O
dimension:	O
23.5cm.	O
Tumor	O
Site:	O
Distal	O
esophagus	O
(lower	O
thoracic	O
esophagus),	O
Esophagogastric	O
junction	O
(EGJ)	O
Relationship	O
of	O
Tumor	O
to	O
Esophagogastric	O
Junction:	O
Cannot	O
be	O
assessed	O
Tumor	O
Size:	O
Cannot	O
be	O
determined	O
(status	O
-	O
post	O
neoadjuvant	O
therapy)	O
Distance	O
of	O
Tumor	O
center	O
from	O
Esophagogastric	O
Junction:	O
Cannot	O
be	O
determined.	O
Microscopic	O
Histologic	O
Type:	O
Adenocarcinoma	O
Histologic	O
Grade:	O
G3:	O
Poorly	O
differentiated	O
Extent	O
of	O
Invasion	O
Primary	O
Tumor	O
(pT):	O
pT2:	O
Tumor	O
invades	O
muscularis	O
propria	O
Regional	O
Lymph	O
Nodes	O
(pN):	O
pN0:	O
No	O
regional	O
lymph	O
node	O
metastasis	O
Lymph	O
nodes:	O
Number	O
of	O
lymph	O
nodes	O
examined:	O
14.	O
Number	O
involved:	O
0	O
Distant	O
metastasis:	O
PMX:	O
Cannot	O
be	O
assessed	O
Margins:	O
Proximal	O
margin:	O
Negative	O
for	O
invasive	O
carcinoma	O
Distal	O
margin:	O
Negative	O
for	O
invasive	O
carcinoma	O
Circumferential	O
(adventitial)	O
margin:	O
Negative	O
for	O
invasive	O
carcinoma	O
Distance	O
from	O
tumor	O
to	O
nearest	O
margin	O
if	O
all	O
margins	O
are	O
negative	O
for	O
invasive	O
carcinoma:	O
9.0	O
mm.	O
Circumferential	O
Treatment	O
Effect	O
(applicable	O
to	O
carcinomas	O
treated	O
with	O
neoadjuvant	O
therapy):	O
Present,	O
Marked	O
response	O
(grade	O
1,	O
minimal	O
residual	O
cancer,	O
single	O
cancer	O
cells	O
or	O
small	O
groups	O
of	O
cancer	O
cells)	O
Lymphatic	O
(small	O
vessel)	O
Invasion:	O
Not	O
identified	O
Venous	O
(large	O
vessel)	O
Invasion:	O
Not	O
identified	O
Perineural	O
Invasion:	O
Not	O
identified	O
TNM	O
Descriptors:	O
y	O
(post-treatment)	O
Additional	O
Pathologic	O
Findings:	O
Esophagitis,	O
Gastritis,	O
H.	O
pyloris	O
immunostains	O
(performed	O
blocks	O
4P	O
and	O
4W)	O
are	O
negative,	O
with	O
satisficatory	O
controls	O
.	O
Imaging/Studies:	O
#	O
Video	O
Swallow	O
Eval	O
(___):	O
Penetration	O
with	O
nectar	O
and	O
silent	O
aspiration	O
with	O
thin	O
liquids.	O
#	O
CXR	O
___	O
compared	O
to	O
the	O
previous	O
radiograph,	O
the	O
preexisting	O
parenchymal	O
opacities	O
have	O
minimally	O
decreased	O
in	O
extent.	O
Parts	O
of	O
these	O
opacities	O
is	O
certainly	O
caused	O
by	O
the	O
surgical	O
intervention,	O
but	O
other	O
parts,	O
notably	O
in	O
the	O
perihilar	O
areas	O
on	O
the	O
left	O
and	O
right,	O
are	O
likely	O
caused	O
by	O
mild-to-moderate	O
pulmonary	O
edema.	O
These	O
edematous	O
changes	O
have	O
decreased	O
in	O
the	O
interval.	O
Also	O
decreased	O
is	O
a	O
moderate	O
left	O
pleural	O
effusion	O
that	O
is	O
better	O
appreciated	O
on	O
the	O
lateral	O
than	O
on	O
the	O
frontal	O
radiograph.	O
No	O
new	O
parenchymal	O
opacities.	O
Unchanged	O
severe	O
cardiomegaly.	O
#	O
UGI	O
(___):	O
1.	O
No	O
esophageal	O
leak.	O
2.	O
Aspiration	O
from	O
small	O
amount	O
of	O
Optiray	O
and	O
thin	O
barium.	O
#	O
EKG	O
(___):	O
Atrial	O
fibrillation	O
with	O
a	O
moderate	O
ventricular	O
response.	O
Low	O
limb	O
lead	O
voltage.	O
ST-T	O
wave	O
flattening	O
in	O
the	O
limb	O
leads.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
___	O
there	O
is	O
variation	O
in	O
precordial	O
lead	O
placement	O
and	O
the	O
T	O
wave	O
abnormalities	O
in	O
leads	O
V3-V6	O
persist	O
without	O
diagnostic	O
interim	O
change.	O
Clinical	O
correlation	O
is	O
suggested.	O
Brief	O
Hospital	O
Course:	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
General	O
Surgical	O
Service	O
on	O
___	O
after	O
minimally	O
invasive	O
esophagogastrectomy	O
with	O
cervical	O
anastomosis	O
and	O
jejunostomy	O
tube	O
placement.	O
The	O
procedure	O
went	O
well	O
without	O
complication	O
(reader	O
referred	O
to	O
the	O
Operative	O
Note	O
for	O
details).	O
Neuro:	O
The	O
patient	O
received	O
dilaudid	O
PCA	O
with	O
good	O
effect	O
and	O
adequate	O
pain	O
control.	O
When	O
tolerating	O
oral	O
intake,	O
the	O
patient	O
was	O
transitioned	O
to	O
oral	O
pain	O
medications.	O
CV:	O
The	O
patient	O
was	O
weaned	O
off	O
pressors	O
on	O
POD1.	O
He	O
remained	O
on	O
telemetry	O
and	O
had	O
intermittent	O
ventricular	O
tachycardia	O
(approx	O
5	O
beats)	O
a	O
few	O
times	O
each	O
day	O
while	O
in	O
hospital.	O
He	O
was	O
asymptomatic.	O
EKG	O
___	O
revealed	O
atrial	O
fibrillation	O
with	O
a	O
moderate	O
ventricular	O
response.	O
The	O
patient's	O
coumadin	O
was	O
restarted	O
at	O
3mg/day	O
(his	O
home	O
dose)	O
on	O
___.	O
His	O
INR	O
returned	O
to	O
therapeutic	O
levels	O
before	O
discharge,	O
and	O
he	O
will	O
follow	O
up	O
with	O
his	O
PCP	O
2	O
days	O
after	O
discharge	O
for	O
continued	O
coumadin	O
management.	O
Pulmonary:	O
The	O
patient	O
was	O
extubated	O
POD1.	O
On	O
POD2,	O
his	O
chest	O
tube	O
was	O
put	O
to	O
waterseal,	O
and	O
he	O
received	O
IV	O
lasix.	O
On	O
POD6,	O
his	O
chest	O
tube	O
was	O
discontinued.	O
He	O
developed	O
worsening	O
shortness	O
of	O
breath	O
on	O
POD	O
8,	O
and	O
was	O
given	O
IV	O
lasix	O
again	O
daily	O
for	O
the	O
next	O
4	O
days.	O
His	O
CXR	O
gradually	O
improved,	O
and	O
he	O
was	O
weaned	O
back	O
to	O
room	O
air.	O
He	O
was	O
able	O
to	O
ambulate	O
without	O
oxygen	O
supplementation	O
at	O
the	O
time	O
of	O
discharge.	O
He	O
will	O
continue	O
furosemide	O
20mg	O
PO	O
for	O
two	O
days	O
after	O
discharge	O
until	O
his	O
appointment	O
with	O
his	O
PCP,	O
who	O
will	O
determine	O
if	O
he	O
needs	O
to	O
continue	O
this	O
medication.	O
Good	O
pulmonary	O
toilet,	O
early	O
ambulation	O
and	O
incentive	O
spirrometry	O
were	O
encouraged	O
throughout	O
hospitalization.	O
GI/GU/FEN:	O
Post-operatively,	O
the	O
patient	O
was	O
made	O
NPO	O
with	O
IV	O
fluids.	O
Diet	O
was	O
advanced	O
when	O
appropriate,	O
which	O
was	O
well	O
tolerated.	O
Patient's	O
intake	O
and	O
output	O
were	O
closely	O
monitored,	O
and	O
IV	O
fluid	O
was	O
adjusted	O
when	O
necessary.	O
Electrolytes	O
were	O
routinely	O
followed,	O
and	O
repleted	O
when	O
necessary.	O
ID:	O
The	O
patient	O
had	O
some	O
purulent	O
drainage	O
from	O
his	O
neck	O
JP	O
site,	O
but	O
remained	O
afebrile.	O
This	O
was	O
followed	O
and	O
diminished	O
progressively	O
during	O
hospitalization.	O
He	O
will	O
have	O
continued	O
daily	O
dry	O
dressing	O
changes	O
as	O
needed	O
through	O
___	O
at	O
home.	O
Hematology:	O
The	O
patient's	O
complete	O
blood	O
count	O
was	O
examined	O
routinely;	O
no	O
transfusions	O
were	O
required.	O
The	O
patient's	O
white	O
blood	O
count	O
and	O
fever	O
curves	O
were	O
closely	O
watched	O
for	O
signs	O
of	O
infection.	O
Prophylaxis:	O
The	O
patient	O
received	O
subcutaneous	O
heparin	O
and	O
venodyne	O
boots	O
were	O
used	O
during	O
this	O
stay;	O
was	O
encouraged	O
to	O
get	O
up	O
and	O
ambulate	O
as	O
early	O
as	O
possible.	O
At	O
the	O
time	O
of	O
discharge,	O
the	O
patient	O
was	O
doing	O
well,	O
afebrile	O
with	O
stable	O
vital	O
signs.	O
The	O
patient	O
was	O
tolerating	O
a	O
regular	O
diet,	O
ambulating,	O
voiding	O
without	O
assistance,	O
and	O
pain	O
was	O
well	O
controlled.	O
The	O
patient	O
received	O
discharge	O
teaching	O
and	O
follow-up	O
instructions	O
with	O
understanding	O
verbalized	O
and	O
agreement	O
with	O
the	O
discharge	O
plan.	O
Medications	O
on	O
Admission:	O
1.	O
Amlodipine	O
10	O
mg	O
PO	O
DAILY	O
2.	O
Hydrochlorothiazide	O
25	O
mg	O
PO	O
DAILY	O
3.	O
LaMOTrigine	O
100	O
mg	O
PO	O
BID	O
4.	O
Tamsulosin	O
0.4	O
mg	O
PO	O
HS	O
5.	O
Temazepam	O
15	O
mg	O
PO	O
HS	O
6.	O
Warfarin	O
3	O
mg	O
PO	O
DAILY16	O
7.	O
Aspirin	O
81	O
mg	O
PO	O
DAILY	O
8.	O
saw	O
___	O
160	O
mg	O
oral	O
Daily	O
Discharge	O
Medications:	O
1.	O
Amlodipine	O
10	O
mg	O
PO	O
DAILY	O
2.	O
Aspirin	O
81	O
mg	O
PO	O
DAILY	O
3.	O
Hydrochlorothiazide	O
25	O
mg	O
PO	O
DAILY	O
4.	O
LaMOTrigine	O
100	O
mg	O
PO	O
BID	O
5.	O
Tamsulosin	O
0.4	O
mg	O
PO	O
HS	O
6.	O
Temazepam	O
15	O
mg	O
PO	O
HS	O
7.	O
Warfarin	O
3	O
mg	O
PO	O
DAILY16	O
8.	O
saw	O
___	O
160	O
mg	O
oral	O
Daily	O
9.	O
OxycoDONE	O
(Immediate	O
Release)	O
5	O
mg	O
PO	O
Q4H:PRN	O
pain	O
RX	O
*oxycodone	O
5	O
mg	O
Half	O
to	O
one	O
tablet(s)	O
by	O
mouth	O
every	O
four	O
(4)	O
hours	O
Disp	O
#*30	O
Tablet	O
Refills:*0	O
10.	O
Acetaminophen	O
650	O
mg	O
PO	O
Q6H:PRN	O
pain	O
Do	O
not	O
exceed	O
4	O
grams	O
in	O
1	O
day.	O
RX	O
*acetaminophen	O
500	O
mg	O
___	O
tablet(s)	O
by	O
mouth	O
every	O
six	O
(6)	O
hours	O
Disp	O
#*60	O
Tablet	O
Refills:*2	O
11.	O
Tube	O
Feeds	O
Tubefeeding:	O
Jevity	O
1.5	O
Full	O
strength;	O
Goal	O
rate:	O
108	O
ml/hr	O
Cycle?:	O
Yes,	O
starting	O
now	O
Cycle	O
start:	O
___	O
Cycle	O
end:	O
0900	O
Residual	O
Check:	O
Q8H	O
Hold	O
feeding	O
for	O
residual	O
>=	O
:	O
200	O
ml	O
Flush	O
w/	O
20	O
water	O
q6h	O
12.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID	O
RX	O
*docusate	O
sodium	O
100	O
mg	O
1	O
capsule(s)	O
by	O
mouth	O
twice	O
a	O
day	O
Disp	O
#*60	O
Capsule	O
Refills:*1	O
13.	O
Furosemide	O
20	O
mg	O
PO	O
DAILY	O
Your	O
primary	O
care	O
doctor	O
___	O
advise	O
if	O
this	O
should	O
be	O
continued	O
beyond	O
2	O
days.	O
RX	O
*furosemide	O
20	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
Daily	O
Disp	O
#*2	O
Tablet	O
Refills:*0	O
14.	O
Multivitamins	O
1	O
TAB	O
PO	O
DAILY	O
RX	O
*multivitamin	O
[Chewable	O
Multi	O
Vitamin]	O
1	O
tablet,chewable(s)	O
by	O
mouth	O
Daily	O
Disp	O
#*100	O
Capsule	O
Refills:*5	O
Discharge	O
Disposition:	O
Home	O
With	O
Service	O
Facility:	O
___	O
Discharge	O
Diagnosis:	O
Esophageal	O
carcinoma	O
Discharge	O
Condition:	O
Mental	O
Status:	O
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Independently_mobile
-	B-Independently_mobile
Independent.	B-Independently_mobile
Discharge	O
Instructions:	O
Please	O
resume	O
all	O
regular	O
home	O
medications,	O
unless	O
specifically	O
advised	O
not	O
to	O
take	O
a	O
particular	O
medication.	O
Also,	O
please	O
take	O
any	O
new	O
medications	O
as	O
prescribed.	O
Please	O
get	O
plenty	O
of	O
rest,	O
continue	O
to	O
ambulate	O
several	O
times	O
per	O
day,	O
and	O
drink	O
adequate	O
amounts	O
of	O
fluids.	O
Avoid	O
lifting	O
weights	O
greater	O
than	O
___	O
lbs	O
until	O
you	O
follow-up	O
with	O
your	O
surgeon,	O
who	O
will	O
instruct	O
you	O
further	O
regarding	O
activity	O
restrictions.	O
Avoid	O
driving	O
or	O
operating	O
heavy	O
machinery	O
while	O
taking	O
pain	O
medications.	O
Please	O
follow-up	O
with	O
your	O
surgeon	O
and	O
Primary	O
Care	O
Provider	O
(PCP)	O
as	O
advised.	O
Incision	O
Care:	O
*Please	O
call	O
your	O
doctor	O
or	O
nurse	O
practitioner	O
if	O
you	O
have	O
increased	O
pain,	O
swelling,	O
redness,	O
or	O
drainage	O
from	O
the	O
incision	O
site.	O
*Avoid	O
swimming	O
and	O
baths	O
until	O
your	O
follow-up	O
appointment.	O
*You	O
may	O
shower,	O
and	O
wash	O
surgical	O
incisions	O
with	O
a	O
mild	O
soap	O
and	O
warm	O
water.	O
Gently	O
pat	O
the	O
area	O
dry.	O
*If	O
you	O
have	O
staples,	O
they	O
will	O
be	O
removed	O
at	O
your	O
follow-up	O
appointment.	O
*If	O
you	O
have	O
steri-strips,	O
they	O
will	O
fall	O
off	O
on	O
their	O
own.	O
Please	O
remove	O
any	O
remaining	O
strips	O
___	O
days	O
after	O
surgery.	O
Followup	O
Instructions:	O
___	O

